Oliver Tomé

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine Shannon, Klaus Baumann et al. · The Lancet Oncology · 2020 · 162 citations

Medicine, Gynecology, Oncology +14

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Marco Colleoni, Weixiu Luo, Per Karlsson et al. · The Lancet Oncology · 2017 · 122 citations

Medicine, Gynecology, Oncology +13

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer

Ignace Vergote, José Alejandro Pérez Fidalgo, Erika Hamilton et al. · Journal of Clinical Oncology · 2023 · 71 citations · Full text

Medicine, Oncology, Pharmacology +15

Early initiation of external beam radiotherapy (EBRT) may increase the risk of long-term toxicity in patients undergoing intraoperative radiotherapy (IORT) as a boost for breast cancer

Frederik Wenz, Grit Welzel, Anke Keller et al. · The Breast · 2008 · 61 citations · Full text

Medicine, Oncology, Radiation Oncology +11